[BidClub_]

PERSON DIRECTORY

Sarah Guo

Host of No Priors. Sarah Guo appears in 71 indexed conversations across No Priors, Invest Like the Best, Latent Space. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.

71 EPISODES3 SHOWS
7 episodes2 active
Language
No PriorsEN · 43 min

Re-Founding Incumbents for the AI Era with Sequence Holdings Co-Founder and CEO Michael Lee

Sarah GuoMichael Lee

Sequence Holdings is pairing frontier engineering with incumbent advantages, partnering with the Dell family office on its $7.7B acquisition of Baldwin.At BankSouth, average consumer-loan underwriting volume fell 94%, timelines dropped from 30 days to 11, and Q2 loan volume doubled versus Q1 without changed standards.Whether Atlas can repeat that operating leverage depends less on code than on the more difficult human engineering problem.

Invest Like the BestEN · 60 min

Sarah Guo - What the 250 People Building AI Believe - [Invest Like the Best, EP.489]

Patrick O'ShaughnessySarah Guo

Sarah Guo says competitive open-source AI is already widespread, so US restrictions could handicap law-abiding American businesses while adversaries ignore them.Her roughly 250-person network sees recursive self-improvement and “some sort of exponential intelligence” as a one-to-two-year possibility, while Sunday Robotics targets home-robot beta by year-end.Compute independence, regulation, and physical supply chains remain constraints, while Chai Discovery’s $10 million contract and customer adoption test AI’s ability to capture value in biology.

No PriorsEN · 39 min

Chasing Trillion-Dollar Companies, Founder Ambition, Token Budgets, & Regulatory Capture

Sarah GuoElad Gil

Anthropic, OpenAI, and SpaceX’s leap toward $1 trillion is a five-year anomaly, while reaching that scale likely requires $50 billion-$100 billion of revenue with good margins.AI’s opportunity may be far larger than current per-seat models imply, but compute bottlenecks, founder exit timing, recursive-self-improvement uncertainty, and token allocation by return on invested tokens remain decisive constraints.

No PriorsEN · 45 min

Re-engineering the Semiconductor Supply Chain with Intel CEO Lip Bu Tan

Sarah GuoElad GilLip-Bu Tan

Lip-Bu Tan’s Intel turnaround starts with faster accountability, balance-sheet repair and product simplification, while inference and agentic AI could lift CPU demand from one per eight GPUs toward one per four or one per one.Intel Foundry remains a costly trust and supply-chain bet against TSMC, with IP, yield and cycle time as the proof points; its potential may surface around 2030–2032 as packaging, power and materials become harder bottlenecks.

No PriorsEN · 58 min

Jared Kushner: BrainCo, Affinity Partners, and the Geopolitics of AI

Jared KushnerSarah GuoElad Gil

Affinity Partners seeks returns through governance judgment, networks, and hands-on execution, while favoring Gulf and Latin American tailwinds and contrarian opportunities such as Albania.BrainCo is productizing reusable AI infrastructure for institutions, with a permitting workflow reduced from over 40 steps to 35 at over 90% accuracy; adoption, talent, project selection, and energy permitting remain key constraints.

No PriorsEN · 28 min

No Priors Ep. 109 | With Sarah and Elad

Sarah GuoElad Gil

Image generation is entering another quality shock, but controllability and seamless vertical workflows matter more commercially than novelty alone.As foundation-model capabilities and product surfaces converge, distribution, consumer surplus, and specialized opportunities in physics, materials, robotics, science, health, and biology become more important.Defensibility depends on proprietary data-generation engines or genuinely different technical theses, while MCP, capital availability, and the next model release could quickly reshape today’s emerging market structure.

No PriorsEN · 41 min

No Priors Ep. 104 | With Flagship Pioneering CEO and Co-Founder Noubar Afeyan

Sarah GuoNoubar Afeyan

Noubar Afeyan’s Flagship Pioneering model treats parallel startup creation as a repeatable institution for underwriting uncertainty, using variation, selection and iteration rather than forecasting breakthroughs.Generate Biomedicines has more than 15 computationally designed antibody programs, but Phase III trials, FDA regulation, pricing power and platform funding remain decisive constraints, as Joule’s technically successful but economically unviable outcome demonstrates.